SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors are keenly focused on recent technical breakouts and the potential for S&P 500 inclusion, with many anticipating a pre-earnings rally. The community is actively debating the impact of recent capital raises and the upcoming stablecoin launch, alongside performance targets for the CEO. Bullish sentiment is countered by concerns over past share dilution and price volatility, though the broader fintech sector's momentum adds to the conversation.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending following highly positive topline Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, which demonstrated strong efficacy and met all primary and secondary endpoints. The biopharmaceutical company's robust data is fueling community excitement over its potential as a best-in-class oral therapy for immune-mediated diseases, with discussions also weighing its competitive landscape and future valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to overwhelming short squeeze speculation, fueled by exorbitant borrow fees, limited share availability, and its inclusion on the Reg SHO list. The community is actively celebrating the stock sustaining above the critical $5 mark, which is seen as a gateway for institutional investment, and expressing high conviction in the groundbreaking potential of its GPS immunotherapy for AML. This confluence of factors, including promising clinical trial progress suggesting significantly extended patient survival, is driving intense discussion around a potential multi-billion dollar buyout and a significant re-rating of the company's value.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its strategic collaboration with OpenAI, enhancing its Athena AI marketing platform with advanced conversational intelligence, an announcement made at CES 2026. This news has ignited strong community discussion, with many anticipating a significant short squeeze given the stock's high short interest and perceived undervaluation. Investors are actively highlighting Zeta's position as a burgeoning leader in the AI-driven MarTech sector and its strengthening fundamentals.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is generating significant buzz following announcements at CES 2026, most notably the integration of its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion Platform ecosystem. The community is highly enthusiastic about this validation and Aeva's new Omni sensor for Physical AI applications, anticipating substantial stock appreciation driven by its low float and perceived technological leadership.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus is trending due to the announcement of a 3D-printed fuel tank for its Vigoride-7 orbital vehicle, sparking excitement around the company's innovation in the space sector. This enthusiasm, however, is heavily contested by community members after a recent private placement was announced, fueling intense debate over potential dilution and the company's financial stability, despite its position in the trending space sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing a significant surge in trading volume, driving strong bullish sentiment and community discussions predicting a notable price ascent. The conversation highlights its foundational technology in IoT and decentralized data, bolstered by Japanese regulatory compliance and anticipated 2026 ecosystem developments, with many viewing it as a long-term investment in a real technology project.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is currently trending following positive Phase 2 clinical data for BMB-101, showing strong efficacy and a clean safety profile in treating drug-resistant epilepsy. This promising update has ignited intense community discussion, with many drawing parallels to prior explosive biotech surges and debating the potential for a significant short squeeze, while others express surprise at the market's reaction despite the scientific advancements.

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a top meme coin on the Injective blockchain, driven by its strong community actively discussing its leveraged performance against INJ and resilience during market downturns. The community highlights NONJA's organic growth, high burned liquidity, and successful NFT collections, positioning it for significant gains as Injective's ecosystem benefits from its robust fundamentals and upcoming ETF considerations.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending following its CES 2026 announcements, where CEO Jensen Huang unveiled the "Vera Rubin" AI platform already in full production, boasting significant performance gains and efficiency, alongside "Alpamayo," an open-source AI model for autonomous vehicles. The community is buzzing about NVIDIA's continued dominance in AI and its strategic expansion into physical AI and robotics, further solidifying its leadership in the evolving market despite short-term stock price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) demonstrated improvement in lung function relative to placebo.The late-stage study enrolled 597 patients across multiple locations, and Tyvaso demonstrated superiority over placebo in terms of the change in absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients with IPF. Absolute forced vital capacity (FVC) is a measurement used to gauge lung health, referring to the total volume of air in liters that a person can forcibly exhale after taking a deep, maximum inhalation.Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown cause. It is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. United Therapeutics estimates there are over 100,000 IPF patients in the United States.<a href="https://stocktwits.com/symbol/UTHR">UTHR stock</a> traded nearly 36% higher at the time of writing. On Stocktwits, retail sentiment around the shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume soared from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_12_13_28_PM_png_dae41f310b.webp" alt="UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the positive data implies more funding for more studies.<stembedurl>https://stocktwits.com/DonnyDonowitz/message/627212165</stembedurl>Another user expects the stock to close at $450.<stembedurl>https://stocktwits.com/wallstreet63/message/627228569</stembedurl>United Therapeutics <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.unither.com/press-releases/2025/09-02-2025-120037033">intends</a> to use the data from both the study and an ongoing study of nebulized Tyvaso to support a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to add IPF to the labeled indications for nebulized Tyvaso. Data from the ongoing study is expected in the first half of 2026, and the company plans to meet with the FDA before the end of the year to discuss ways to expedite the review process once the data is in, the company said.Following the announcement, multiple analysts hiked their price target on UTHR.<ul style="list-style-type:square;"><li>BofA raised its price target to $463 from $314 and kept a ‘Neutral’ rating on the shares. The firm said that the results were “surprisingly positive” and added that it expects $2.5 billion risk-adjusted peak sales for the drug in IPF.&nbsp;</li><li>Jefferies analyst Roger Song raised the firm's price target to $564 from $432 while keeping a ‘Buy’ rating on the shares.</li></ul>UTHR stock is up by 17% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-stock-plunges-after-announcing-cost-cutting-measures/chv6vkKRdF3">Why Did Bollinger Innovations Stock Plunge 18% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside

The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial. 

Equity

GraniteShares ETF Trust - Graniteshares Nasdaq Select Disruptors ETF

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$66.22
Prev Close	$65.78
Open	$66.45
Dividend Yield	N/A
50-Day Moving Average	$67.21
Beta	N/A
Avg. Volume	1,360.09
PE Ratio	N/A

52-Week High	$68.88
52-Week Low	$44.61
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUP
GraniteShares Nasdaq Select Disruptors ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DRUP News

DRUPGraniteShares Nasdaq Select Disruptors ETF